search tools

You'll have to wait 100 years for John Malkovich's latest movie

Edit Atlanta Journal 06 May 2016
It turns out "100 Years" is actually a promotion for Louis XIII cognac, which bills itself as "One century in a bottle" because "each decanter takes four generations of cellar masters over 100 years to craft." ... And the Louis XIII website has a handy countdown clock for your great-grandchildren to keep track of the release date ... Louis XIII is giving ......

Holding(s) in Company (Cambian Group plc)

Edit Public Technologies 05 May 2016
(Source. Cambian Group plc) TR-1. NOTIFICATION OF MAJOR INTEREST IN SHARES. TR-1. NOTIFICATION OF MAJOR INTEREST IN SHARESi. 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached. ii. Cambian Group Plc. 2 Reason for the notification (please tick the appropriate box or boxes).. An acquisition or disposal of voting rights. X ... An event changing the breakdown of voting rights ... 3 ... iii ... 4 ... 5 ... v ... date xiii....

Holding(s) in Company (Tullett Prebon plc)

Edit Public Technologies 05 May 2016
(Source. Tullett Prebon plc) d461146b-4df3-4435-9ca2-ccf87f6fe94c.pdf For filings with the FCA include the annex. For filings with issuer exclude the annex. TR-1. NOTIFICATION OF MAJOR INTEREST IN SHARESi. 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached. ii. Tullett Prebon plc. 2 Reason for the notification (please tick the appropriate box or boxes). ...  ... . 3 ... iii ... 4 ... 5 ... Expiration date xiii....

Holding(s) in Company (Tullett Prebon Group Ltd)

Edit Public Technologies 05 May 2016
(Source. Tullett Prebon Group Ltd) f1cb8784-405b-4b2b-ac11-1648013344be.pdf For filings with the FCA include the annex. For filings with issuer exclude the annex. TR-1. NOTIFICATION OF MAJOR INTEREST IN SHARESi. 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached. ii. Tullett Prebon plc. 2 Reason for the notification (please tick the appropriate box or boxes). ...  ... . 3 ... 4 ... Expiration date xiii....

InspireMD Announces Late-Breaking Trial Presentation on CGuardTM Embolic Prevention System at EuroPCR 2016 Conference (InspireMD Inc)

Edit Public Technologies 05 May 2016
and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign ......

M�xico realizar� Semana de la Diversidad Biol�gica rumbo a cumbre de Canc�n

Edit Naples Daily News 05 May 2016
"El lema de la Sexta Semana es Biodiversidad es Bienestar. Con ello, el evento abre paso al tema oficial de la XIII Conferencia de las Partes del Convenio sobre Diversidad Biológica de Naciones Unidas (COP13)" que México acogerá en diciembre de 2016 en Cancún, señaló en un boletín la Comisión Nacional para el Conocimiento y Uso de la Biodiversidad (Conabio) ... ....

Kimco Realty Announces Pricing of $150 Million 4.25% Notes Due 2045

Edit Stockhouse 05 May 2016
Factors which may cause actual results to differ materially from current expectations include, but are not limited to, (i) general adverse economic and local real estate conditions, (ii) the inability of major tenants to continue paying their rent obligations due to bankruptcy, insolvency or a general downturn in their business, (iii) financing ......

Kimco Realty Announces Pricing of $150 Million 4.25% Notes Due 2045 (Kimco Realty Corporation)

Edit Public Technologies 05 May 2016
Factors which may cause actual results to differ materially from current expectations include, but are not limited to, (i) general adverse economic and local real estate conditions, (ii) the inability of major tenants to continue paying their rent obligations due to bankruptcy, insolvency or a general downturn in their business, (iii) financing ......

Letter to Shareholders for Rights Issue (CuDeco Limited)

Edit Public Technologies 05 May 2016
The Rights Issue will be available to all registered shareholders who hold shares at 7.00pm Perth time on Friday 15 April 2016 (Record Date) with registered addresses in Australia, New Zealand, Hong Kong, Singapore (to the extent that the Shareholders are exempt under Subdivision 4, Division 1 of Part XIII of the Securities and Futures Act, Chapter ......

Announcement of Entitlement Offer – May 2016 (Somnomed Limited)

Edit Public Technologies 05 May 2016
... whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part XIII of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA"), or as otherwise pursuant to , and in accordance with the conditions of any other applicable provisions of the SFA....

Focus Graphite Closes Second Tranche of Non-Brokered Offering (Focus Graphite Inc)

Edit Public Technologies 05 May 2016
... (xii) the risks associated with the various environmental regulations the Company is subject to; (xiii) risks related to regulatory and permitting delays; (xiv) risks related to potential conflicts of interest; (xv) the reliance on key personnel; (xvi) liquidity risks; and (xvii) the risk of potential dilution through the issue of common shares....

Prospectus for Rights Issue (CuDeco Limited)

Edit Public Technologies 05 May 2016
... or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part XIII of the Securities and Futures Act, Chapter 289 of Singapore (SFA), or as otherwise pursuant to, and in accordance with the conditions of any other applicable provisions of the SFA....

Caladrius Biosciences Reports 2016 First Quarter Financial Results (Caladrius Biosciences Inc)

Edit Public Technologies 05 May 2016
(i) our expected continued losses and negative cash flows; (ii) our anticipated need for substantial additional financing; (iii) the significant costs and management resources required to comply with the requirements of being a public company; (iv) the possibility that a significant market for cell therapy may not emerge; (v) the potential ......
×
×
×
×